Enhertu Liquid
NDC Package 83012-020-99
Package Information
Enhertu liquids is trastuzumab is used to treat certain breast or stomach cancers that produce more than the normal amount of a certain substance called HER2 protein. This formulation utilizes a liquid delivery system. Marketed by Boehringer Ingelheim Fremont, Inc., this product is identified by NDC 83012-020.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 83012 - Boehringer Ingelheim Fremont, Inc.
- 83012-020 -
- 83012-020-99 - 22 mg in 1 BAG
- 83012-020 -
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83012-020-99 identifies a specific commercial package of 22 mg in 1 bag of Enhertu (UNFINISHED drug), a bulk ingredient labeled by Boehringer Ingelheim Fremont, Inc.. This liquid is formulated for use and contains trastuzumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Boehringer Ingelheim Fremont, Inc. on May 20, 2019. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Trastuzumab is used to treat certain breast or stomach cancers that produce more than the normal amount of a certain substance called HER2 protein. Trastuzumab belongs to a class of medications known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. This monograph is about the following trastuzumab products: trastuzumab, trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp.
How is this Boehringer Ingelheim Fremont, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83012002099. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.